COVID-19 Impact on Global Drugs for Central Nervous System Diseases Market Size, Status and Forecast 2020-2026

August 2020 | 92 pages | ID: C981285166C6EN
QYResearch

Abstracts

This report focuses on the global Drugs for Central Nervous System Diseases status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Drugs for Central Nervous System Diseases development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Alkermes
• Astrazeneca
• Biogen
• Bristol Myers Squibb
• Lilly
• GSK
• Merck
• Sunovion?Pharmaceuticals
• Pfizer
• Teva
• Norvatis

Market segment by Type, the product can be split into

• Antidepressants
• Anxiolytics
• Anti-manic
• Other

Market segment by Application, split into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Drugs for Central Nervous System Diseases status, future forecast, growth opportunity, key market and key players.
• To present the Drugs for Central Nervous System Diseases development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Drugs for Central Nervous System Diseases are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue
1.4 Market Analysis by Type
  1.4.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Antidepressants
  1.4.3 Anxiolytics
  1.4.4 Anti-manic
  1.4.5 Other
1.5 Market by Application
  1.5.1 Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2026
  1.5.2 Hospital Pharmacies
  1.5.3 Retail Pharmacies
  1.5.4 Online Pharmacies
1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Central Nervous System Diseases Industry Impact
  1.6.1 How the Covid-19 is Affecting the Drugs for Central Nervous System Diseases Industry
    1.6.1.1 Drugs for Central Nervous System Diseases Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Drugs for Central Nervous System Diseases Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Drugs for Central Nervous System Diseases Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Drugs for Central Nervous System Diseases Market Perspective (2015-2026)
2.2 Drugs for Central Nervous System Diseases Growth Trends by Regions
  2.2.1 Drugs for Central Nervous System Diseases Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Drugs for Central Nervous System Diseases Historic Market Share by Regions (2015-2020)
  2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Drugs for Central Nervous System Diseases Market Growth Strategy
  2.3.6 Primary Interviews with Key Drugs for Central Nervous System Diseases Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Drugs for Central Nervous System Diseases Players by Market Size
  3.1.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue (2015-2020)
  3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2015-2020)
  3.1.3 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Drugs for Central Nervous System Diseases Market Concentration Ratio
  3.2.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2019
3.3 Drugs for Central Nervous System Diseases Key Players Head office and Area Served
3.4 Key Players Drugs for Central Nervous System Diseases Product Solution and Service
3.5 Date of Enter into Drugs for Central Nervous System Diseases Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2021-2026)

5 DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)
5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Drugs for Central Nervous System Diseases Market Size (2015-2020)
6.2 Drugs for Central Nervous System Diseases Key Players in North America (2019-2020)
6.3 North America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
6.4 North America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Drugs for Central Nervous System Diseases Market Size (2015-2020)
7.2 Drugs for Central Nervous System Diseases Key Players in Europe (2019-2020)
7.3 Europe Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
7.4 Europe Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

8 CHINA

8.1 China Drugs for Central Nervous System Diseases Market Size (2015-2020)
8.2 Drugs for Central Nervous System Diseases Key Players in China (2019-2020)
8.3 China Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
8.4 China Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Drugs for Central Nervous System Diseases Market Size (2015-2020)
9.2 Drugs for Central Nervous System Diseases Key Players in Japan (2019-2020)
9.3 Japan Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
9.4 Japan Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Drugs for Central Nervous System Diseases Market Size (2015-2020)
10.2 Drugs for Central Nervous System Diseases Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
10.4 Southeast Asia Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

11 INDIA

11.1 India Drugs for Central Nervous System Diseases Market Size (2015-2020)
11.2 Drugs for Central Nervous System Diseases Key Players in India (2019-2020)
11.3 India Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
11.4 India Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Drugs for Central Nervous System Diseases Market Size (2015-2020)
12.2 Drugs for Central Nervous System Diseases Key Players in Central & South America (2019-2020)
12.3 Central & South America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020)
12.4 Central & South America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Alkermes
  13.1.1 Alkermes Company Details
  13.1.2 Alkermes Business Overview and Its Total Revenue
  13.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction
  13.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2015-2020))
  13.1.5 Alkermes Recent Development
13.2 Astrazeneca
  13.2.1 Astrazeneca Company Details
  13.2.2 Astrazeneca Business Overview and Its Total Revenue
  13.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction
  13.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.2.5 Astrazeneca Recent Development
13.3 Biogen
  13.3.1 Biogen Company Details
  13.3.2 Biogen Business Overview and Its Total Revenue
  13.3.3 Biogen Drugs for Central Nervous System Diseases Introduction
  13.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.3.5 Biogen Recent Development
13.4 Bristol Myers Squibb
  13.4.1 Bristol Myers Squibb Company Details
  13.4.2 Bristol Myers Squibb Business Overview and Its Total Revenue
  13.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction
  13.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.4.5 Bristol Myers Squibb Recent Development
13.5 Lilly
  13.5.1 Lilly Company Details
  13.5.2 Lilly Business Overview and Its Total Revenue
  13.5.3 Lilly Drugs for Central Nervous System Diseases Introduction
  13.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.5.5 Lilly Recent Development
13.6 GSK
  13.6.1 GSK Company Details
  13.6.2 GSK Business Overview and Its Total Revenue
  13.6.3 GSK Drugs for Central Nervous System Diseases Introduction
  13.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.6.5 GSK Recent Development
13.7 Merck
  13.7.1 Merck Company Details
  13.7.2 Merck Business Overview and Its Total Revenue
  13.7.3 Merck Drugs for Central Nervous System Diseases Introduction
  13.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.7.5 Merck Recent Development
13.8 Sunovion?Pharmaceuticals
  13.8.1 Sunovion?Pharmaceuticals Company Details
  13.8.2 Sunovion?Pharmaceuticals Business Overview and Its Total Revenue
  13.8.3 Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Introduction
  13.8.4 Sunovion?Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.8.5 Sunovion?Pharmaceuticals Recent Development
13.9 Pfizer
  13.9.1 Pfizer Company Details
  13.9.2 Pfizer Business Overview and Its Total Revenue
  13.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction
  13.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.9.5 Pfizer Recent Development
13.10 Teva
  13.10.1 Teva Company Details
  13.10.2 Teva Business Overview and Its Total Revenue
  13.10.3 Teva Drugs for Central Nervous System Diseases Introduction
  13.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  13.10.5 Teva Recent Development
13.11 Norvatis
  10.11.1 Norvatis Company Details
  10.11.2 Norvatis Business Overview and Its Total Revenue
  10.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction
  10.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2015-2020)
  10.11.5 Norvatis Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Drugs for Central Nervous System Diseases Key Market Segments
Table 2. Key Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue
Table 3. Ranking of Global Top Drugs for Central Nervous System Diseases Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Antidepressants
Table 6. Key Players of Anxiolytics
Table 7. Key Players of Anti-manic
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Drugs for Central Nervous System Diseases Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Drugs for Central Nervous System Diseases Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Drugs for Central Nervous System Diseases Players to Combat Covid-19 Impact
Table 14. Global Drugs for Central Nervous System Diseases Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Drugs for Central Nervous System Diseases Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Drugs for Central Nervous System Diseases Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Drugs for Central Nervous System Diseases Market Share by Regions (2015-2020)
Table 18. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Drugs for Central Nervous System Diseases Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Drugs for Central Nervous System Diseases Market Growth Strategy
Table 24. Main Points Interviewed from Key Drugs for Central Nervous System Diseases Players
Table 25. Global Drugs for Central Nervous System Diseases Revenue by Players (2015-2020) (Million US$)
Table 26. Global Drugs for Central Nervous System Diseases Market Share by Players (2015-2020)
Table 27. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2019)
Table 28. Global Drugs for Central Nervous System Diseases by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Drugs for Central Nervous System Diseases Product Solution and Service
Table 31. Date of Enter into Drugs for Central Nervous System Diseases Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 34. Global Drugs for Central Nervous System Diseases Market Size Share by Type (2015-2020)
Table 35. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2021-2026)
Table 36. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2015-2020)
Table 37. Global Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 38. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2021-2026)
Table 39. North America Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 41. North America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 42. North America Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 43. North America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 44. North America Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 45. Europe Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 47. Europe Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 49. Europe Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 51. China Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 52. China Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 53. China Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 54. China Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 55. China Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 56. China Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 57. Japan Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 59. Japan Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 61. Japan Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 65. Southeast Asia Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 67. Southeast Asia Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 69. India Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 70. India Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 71. India Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 72. India Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 73. India Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 74. India Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Drugs for Central Nervous System Diseases Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Drugs for Central Nervous System Diseases Market Share (2019-2020)
Table 77. Central & South America Drugs for Central Nervous System Diseases Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Drugs for Central Nervous System Diseases Market Share by Type (2015-2020)
Table 79. Central & South America Drugs for Central Nervous System Diseases Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Drugs for Central Nervous System Diseases Market Share by Application (2015-2020)
Table 81. Alkermes Company Details
Table 82. Alkermes Business Overview
Table 83. Alkermes Product
Table 84. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 85. Alkermes Recent Development
Table 86. Astrazeneca Company Details
Table 87. Astrazeneca Business Overview
Table 88. Astrazeneca Product
Table 89. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 90. Astrazeneca Recent Development
Table 91. Biogen Company Details
Table 92. Biogen Business Overview
Table 93. Biogen Product
Table 94. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 95. Biogen Recent Development
Table 96. Bristol Myers Squibb Company Details
Table 97. Bristol Myers Squibb Business Overview
Table 98. Bristol Myers Squibb Product
Table 99. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 100. Bristol Myers Squibb Recent Development
Table 101. Lilly Company Details
Table 102. Lilly Business Overview
Table 103. Lilly Product
Table 104. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 105. Lilly Recent Development
Table 106. GSK Company Details
Table 107. GSK Business Overview
Table 108. GSK Product
Table 109. GSK Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 110. GSK Recent Development
Table 111. Merck Company Details
Table 112. Merck Business Overview
Table 113. Merck Product
Table 114. Merck Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 115. Merck Recent Development
Table 116. Sunovion?Pharmaceuticals Business Overview
Table 117. Sunovion?Pharmaceuticals Product
Table 118. Sunovion?Pharmaceuticals Company Details
Table 119. Sunovion?Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 120. Sunovion?Pharmaceuticals Recent Development
Table 121. Pfizer Company Details
Table 122. Pfizer Business Overview
Table 123. Pfizer Product
Table 124. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 125. Pfizer Recent Development
Table 126. Teva Company Details
Table 127. Teva Business Overview
Table 128. Teva Product
Table 129. Teva Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 130. Teva Recent Development
Table 131. Norvatis Company Details
Table 132. Norvatis Business Overview
Table 133. Norvatis Product
Table 134. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2015-2020) (Million US$)
Table 135. Norvatis Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Drugs for Central Nervous System Diseases Market Share by Type: 2020 VS 2026
Figure 2. Antidepressants Features
Figure 3. Anxiolytics Features
Figure 4. Anti-manic Features
Figure 5. Other Features
Figure 6. Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Drugs for Central Nervous System Diseases Report Years Considered
Figure 11. Global Drugs for Central Nervous System Diseases Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Drugs for Central Nervous System Diseases Market Share by Regions: 2020 VS 2026
Figure 13. Global Drugs for Central Nervous System Diseases Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Drugs for Central Nervous System Diseases Market Share by Players in 2019
Figure 16. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2019
Figure 18. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Drugs for Central Nervous System Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Alkermes Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 27. Astrazeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 29. Biogen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 31. Bristol Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 33. Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 35. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 37. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 39. Sunovion?Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Sunovion?Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 41. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 43. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 45. Norvatis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2015-2020)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed